More Articles

Access and Evidence

The Price Of Access

Lucy Fulford, (Nov 13, 2017)

With tight purse strings right across the world, innovative pricing schemes are a crucial step in delivering affordable healthcare
Access and Evidence

A Bright Future

Lucy Fulford, (Nov 9, 2017)

Innovation is disrupting the entire healthcare continuum, creating opportunities for Medical Affairs in new and exciting places, says BMS’ Lav Parvathenani.
Access and Evidence

Surfing The Data Tsunami

Danielle Barron, (Nov 8, 2017)

How pharma is working together with government, regulators, tech companies and their industry peers to establish a strong foundation for health data across Europe
Patients and Medical

Digging For Gold

Lucy Fulford, (Nov 1, 2017)

As Medical gets more involved in real-world evidence, what challenges does it face in proving the value of a medicine?
Access and Evidence

Under Pressure

Hugh Gosling, (Oct 31, 2017)

Pharma must lay its cards on the table and build a more transparent relationship with payers
Access and Evidence

Transformers

Hugh Gosling, (Oct 26, 2017)

An expert powerhouse involved in key strategic decisions right across the lifecycle, Market Access has come a long way in a short time
Patients and Medical

MSLs: The Superheroes of Pharma?

Lucy Fulford, (Oct 25, 2017)

MSLs are pharma’s elite, with the knowledge and interpersonal skills to engage and collaborate with customers. But is pharma asking too much of its scientific superheroes?
Commercial

The Digital Disruption

Adam Chapman, (Oct 23, 2017)

When it comes to customer experience in the digital space, pharma is being outpaced and outsmarted. What can the industry do to change the status quo?
Patients and Medical

Patient-Centricity: Cracking The Formula

Adam Chapman, (Oct 19, 2017)

Novartis Spain’s Cesar Concepcion is on a mission to champion the patient
Commercial

Fly On The Wall

Danielle Barron, (Oct 18, 2017)

Social listening can help pharma understand their customers from a whole new perspective

Pages